CN103874710B - 细胞渗透型抗dna抗体和其抑制dna修复的用途 - Google Patents
细胞渗透型抗dna抗体和其抑制dna修复的用途 Download PDFInfo
- Publication number
- CN103874710B CN103874710B CN201280025431.2A CN201280025431A CN103874710B CN 103874710 B CN103874710 B CN 103874710B CN 201280025431 A CN201280025431 A CN 201280025431A CN 103874710 B CN103874710 B CN 103874710B
- Authority
- CN
- China
- Prior art keywords
- cells
- dna
- cancer
- antibody
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470918P | 2011-04-01 | 2011-04-01 | |
| US61/470,918 | 2011-04-01 | ||
| PCT/US2012/031860 WO2012135831A1 (en) | 2011-04-01 | 2012-04-02 | Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103874710A CN103874710A (zh) | 2014-06-18 |
| CN103874710B true CN103874710B (zh) | 2018-03-27 |
Family
ID=46147672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280025431.2A Active CN103874710B (zh) | 2011-04-01 | 2012-04-02 | 细胞渗透型抗dna抗体和其抑制dna修复的用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9701740B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3597665A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6178785B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103874710B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2744840T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012135831A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6178785B2 (ja) | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーYale University | 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用 |
| US9732146B2 (en) | 2012-03-30 | 2017-08-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Antibody-mediated transduction of heat shock proteins into living cells |
| US12195550B2 (en) | 2012-03-30 | 2025-01-14 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US9512486B2 (en) * | 2012-08-06 | 2016-12-06 | The Institute Of Cancer Research: Royal Cancer Hospital | Materials, methods, and systems for treating cancer |
| EP2968371A4 (en) * | 2013-03-12 | 2017-04-12 | The Board of Trustees of the Leland Stanford Junior University | Modulation of cellular dna repair activity to intercept malignancy |
| KR102522346B1 (ko) * | 2013-08-29 | 2023-04-17 | 시티 오브 호프 | 세포침투 콘주게이트 및 이의 사용 방법 |
| EP3073825A4 (en) * | 2013-11-25 | 2017-06-21 | The University of Toledo | Inhibitors of ercc1-xpf and methods of using the same |
| WO2015106290A1 (en) * | 2014-01-13 | 2015-07-16 | Valerion Therapeutics, Llc | Internalizing moieties |
| WO2015134607A1 (en) | 2014-03-04 | 2015-09-11 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations |
| US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
| KR101602876B1 (ko) | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR101602870B1 (ko) * | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| CA2995673A1 (en) * | 2014-08-27 | 2016-03-03 | Valerion Therapeutics, Llc | Internalizing moieties for treatment of cancer |
| JP2017534571A (ja) * | 2014-08-28 | 2017-11-24 | イェール ユニバーシティーYale University | 抗体3e10の多価フラグメントおよびその使用方法 |
| US10383945B2 (en) * | 2015-02-18 | 2019-08-20 | The United States of America as Represented by the Department of Verterans Affairs | Methods for DNA-dependent targeting of a cell permeant antibody |
| JP2019520086A (ja) | 2016-05-27 | 2019-07-18 | オラム・セラピューティクス・インコーポレイテッド | 細胞質浸透抗体およびその用途 |
| EP3471777A1 (en) | 2016-06-15 | 2019-04-24 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| US12486318B2 (en) | 2016-06-15 | 2025-12-02 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| US11613590B2 (en) * | 2017-07-17 | 2023-03-28 | Nucleus Therapeutics Pty. Ltd | Binding proteins 1 |
| US11129894B2 (en) * | 2017-09-29 | 2021-09-28 | - Humanetics Corporation | Sensitizing cells to proton radiation |
| EP3502700A1 (en) * | 2017-12-21 | 2019-06-26 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods based on the detection of rad51 foci in tumor cells |
| US12304970B2 (en) | 2018-02-01 | 2025-05-20 | Yale University | Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus |
| US20210137960A1 (en) | 2018-02-01 | 2021-05-13 | Yale University | Compositions and methods for inhibition of nuclear-penetrating antibodies |
| KR20190143826A (ko) | 2018-06-21 | 2019-12-31 | 오름테라퓨틱 주식회사 | 세포/조직 특이적 세포 침투 항체 |
| EP3844287B1 (en) | 2018-08-31 | 2024-05-22 | Yale University | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| WO2021015986A1 (en) * | 2019-07-19 | 2021-01-28 | Dana-Farber Cancer Institute, Inc. | Cancer vaccine compositions and methods for using same to prevent and/or treat cancer |
| KR20220101073A (ko) | 2019-08-30 | 2022-07-19 | 예일 유니버시티 | 핵산을 세포로 전달하기 위한 조성물 및 방법 |
| WO2021077070A1 (en) | 2019-10-18 | 2021-04-22 | Yale University | Compositions and methods for inhibition of cell-penetrating antibodies |
| CN116171152A (zh) * | 2020-09-15 | 2023-05-26 | 昂科因凡特公司 | 制备的镭-224和子代联合dna修复抑制剂,用于放射性核素治疗 |
| EP4396225A4 (en) * | 2021-08-30 | 2025-07-02 | Nucleus Therapeutics Pty Ltd | METHOD OF TREATMENT |
| CN115998885B (zh) * | 2021-10-22 | 2024-11-12 | 上海科技大学 | 抑制剂组合及其在制备治疗myc高表达癌症的药物中的应用 |
| CN116120398B (zh) * | 2023-02-23 | 2024-08-23 | 南开大学 | 多肽kwqrksirh、制备方法及其在增敏致dna损伤类肿瘤疗法中的应用 |
| WO2025111420A1 (en) * | 2023-11-21 | 2025-05-30 | Oklahoma Medical Research Foundation | Fully human dna binding monoclonal antibodies |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008091911A2 (en) * | 2007-01-22 | 2008-07-31 | The Regents Of The University Of California | Use of antibody conjugates |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4812397A (en) | 1987-02-10 | 1989-03-14 | The Regents Of The University Of California | MAB-anti-DNA related to nephritis |
| US20030109475A1 (en) | 1991-12-17 | 2003-06-12 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| ES2150573T3 (es) * | 1994-06-24 | 2000-12-01 | Vladimir P Torchilin | Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales. |
| WO1997032602A1 (en) | 1996-03-08 | 1997-09-12 | The Regents Of The University Of California | DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF |
| AU2001257001A1 (en) | 2000-04-10 | 2001-10-23 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
| WO2004033705A2 (en) | 2001-10-10 | 2004-04-22 | Mount Sinai School Of Medicine Of The City University Of New York | Viral interferon antagonists and uses therefor |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| GB0229251D0 (en) | 2002-12-13 | 2003-01-22 | Koninkl Philips Electronics Nv | Internet and tv data service browsing apparatus |
| WO2004066961A2 (en) | 2003-01-20 | 2004-08-12 | St. Jude Children's Research Hospital | Use of sendai virus as a human parainfluenza vaccine |
| US7595379B2 (en) | 2003-05-30 | 2009-09-29 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
| RU2269356C2 (ru) * | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения онкологических заболеваний |
| EP1666055A4 (en) | 2003-07-14 | 2010-02-10 | Viktor Veniaminovich Tets | METHOD OF TREATMENT OF ONCOLOGICAL, INFECTIOUS, AND SOMATIC DISEASES, METHODS OF MONITORING THE EFFICACY OF TREATMENT, AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| JP2007526253A (ja) | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫刺激性ウイルスrnaオリゴヌクレオチド |
| US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
| EP1968643A2 (en) | 2005-12-16 | 2008-09-17 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids into a cell |
| FR2899902B1 (fr) | 2006-04-18 | 2012-01-27 | Agronomique Inst Nat Rech | Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet et leurs utilisations pour la vaccination et la vectorisation intra-cellulaire. |
| WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| GB0615662D0 (en) | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
| JP4936482B2 (ja) | 2007-04-13 | 2012-05-23 | 独立行政法人産業技術総合研究所 | 改良された持続感染型センダイウイルスベクター |
| JP2010527618A (ja) * | 2007-05-24 | 2010-08-19 | アメリカ合衆国 | ヌクレオシドサルベージ経路を通しての核内タンパク質伝達 |
| CA2692072A1 (en) * | 2007-06-13 | 2008-12-24 | Massachusetts Institute Of Technology | Methods and agents for inhibiting tumor growth |
| EP2200652B1 (en) | 2007-09-27 | 2018-03-21 | Children's Medical Center Corporation | Microbubbles and methods for oxygen delivery |
| EP2279002B1 (en) * | 2008-04-30 | 2013-08-14 | Ajou University Industry-Academic Cooperation Foundation | Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same |
| CN102037058B (zh) | 2008-05-23 | 2013-08-07 | 那野伽利阿株式会社 | 多西紫杉醇高分子衍生物、及其制造方法及其用途 |
| CN101808668B (zh) | 2008-07-29 | 2012-06-27 | 那野伽利阿株式会社 | 药物内包活性靶向型高分子微团、医药组合物 |
| CA2777486A1 (en) | 2008-10-15 | 2010-04-22 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotonic dystrophy |
| CN102209726A (zh) | 2008-11-11 | 2011-10-05 | 亚州大学校产学协力团 | 具有细胞穿透性、序列特异性和核酸水解性的抗体、其制备方法及包含所述抗体的药物组合物 |
| US9155801B2 (en) | 2009-05-28 | 2015-10-13 | The United States Government As Represented By The Department Of Veterans Affairs | Amino acid sequences which enhance peptide conjugate solubility |
| US9365866B2 (en) | 2009-06-03 | 2016-06-14 | National Institute Of Advanced Industrial Science And Technology | Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same |
| US8496941B2 (en) | 2009-06-03 | 2013-07-30 | National Institute Of Advanced Industrial Science And Technology | Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same |
| AU2010260145B2 (en) | 2009-06-15 | 2015-08-20 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides |
| EP2477550A4 (en) | 2009-09-15 | 2013-12-04 | Univ Columbia | SYSTEMS, METHODS AND DEVICES FOR MICROBUBBLES |
| WO2012145125A1 (en) | 2011-03-25 | 2012-10-26 | 4S3 Bioscience Inc. | Targeted radionuclides |
| JP6178785B2 (ja) | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーYale University | 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用 |
| JP5921119B2 (ja) | 2011-09-02 | 2016-05-24 | 株式会社東芝 | X線診断装置 |
| WO2013096835A1 (en) | 2011-12-23 | 2013-06-27 | Abbvie Inc. | Stable protein formulations |
| US9610362B2 (en) | 2012-03-16 | 2017-04-04 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of DMPK |
| US9732146B2 (en) | 2012-03-30 | 2017-08-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Antibody-mediated transduction of heat shock proteins into living cells |
| US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US10555911B2 (en) | 2012-05-04 | 2020-02-11 | Yale University | Highly penetrative nanocarriers for treatment of CNS disease |
| US20150152170A1 (en) | 2012-05-23 | 2015-06-04 | Valerion Therapeutics, Llc | Methods for increasing muscle contractility |
| EP3415525B1 (en) | 2012-12-07 | 2022-01-05 | Phion Therapeutics Limited | An amphipathic peptide |
| WO2014130722A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of forbes-cori disease |
| JP2016514096A (ja) | 2013-02-20 | 2016-05-19 | バレリオン セラピューティクス, エルエルシー | ポンぺ病の処置のための方法および組成物 |
| US20160114058A1 (en) | 2013-05-17 | 2016-04-28 | Nanocarrier Co., Ltd. | Polymer micelle pharmaceutical composition |
| WO2015106290A1 (en) | 2014-01-13 | 2015-07-16 | Valerion Therapeutics, Llc | Internalizing moieties |
| WO2015134607A1 (en) | 2014-03-04 | 2015-09-11 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations |
| EP3154570A4 (en) | 2014-06-13 | 2017-12-27 | Valerion Therapeutics, LLC | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders |
| US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
| WO2016013870A1 (ko) | 2014-07-22 | 2016-01-28 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| CA2995673A1 (en) | 2014-08-27 | 2016-03-03 | Valerion Therapeutics, Llc | Internalizing moieties for treatment of cancer |
| JP2017534571A (ja) | 2014-08-28 | 2017-11-24 | イェール ユニバーシティーYale University | 抗体3e10の多価フラグメントおよびその使用方法 |
| WO2016054509A1 (en) | 2014-10-02 | 2016-04-07 | Q-State Biosciences, Inc. | Systems and methods for assessing inter-cell communication |
| US10383945B2 (en) | 2015-02-18 | 2019-08-20 | The United States of America as Represented by the Department of Verterans Affairs | Methods for DNA-dependent targeting of a cell permeant antibody |
| EP3471777A1 (en) | 2016-06-15 | 2019-04-24 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| US12486318B2 (en) | 2016-06-15 | 2025-12-02 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| CA3036524A1 (en) | 2016-09-09 | 2018-03-15 | Valerion Therapeutics, Llc | Methods and compositions for treatment of lafora disease |
| US11613590B2 (en) | 2017-07-17 | 2023-03-28 | Nucleus Therapeutics Pty. Ltd | Binding proteins 1 |
| JP2021518840A (ja) | 2018-03-15 | 2021-08-05 | バレリオン セラピューティクス, エルエルシー | ポリグルコサン障害の処置のための方法及び組成物 |
| BR112021003823A2 (pt) | 2018-08-31 | 2021-05-25 | Yale University | composição, composição farmacêutica e método para modificar o genoma de uma célula |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| EP3844287B1 (en) | 2018-08-31 | 2024-05-22 | Yale University | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
-
2012
- 2012-04-02 JP JP2014502905A patent/JP6178785B2/ja active Active
- 2012-04-02 ES ES12722943T patent/ES2744840T3/es active Active
- 2012-04-02 WO PCT/US2012/031860 patent/WO2012135831A1/en not_active Ceased
- 2012-04-02 EP EP19176246.7A patent/EP3597665A1/en active Pending
- 2012-04-02 CN CN201280025431.2A patent/CN103874710B/zh active Active
- 2012-04-02 EP EP12722943.3A patent/EP2694555B1/en active Active
- 2012-04-02 US US14/009,327 patent/US9701740B2/en active Active
-
2016
- 2016-02-15 JP JP2016025916A patent/JP2016094479A/ja not_active Withdrawn
-
2017
- 2017-06-06 US US15/615,416 patent/US10961301B2/en active Active
-
2021
- 2021-03-05 US US17/193,933 patent/US20220017609A1/en not_active Abandoned
-
2024
- 2024-03-05 US US18/596,375 patent/US20240247056A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008091911A2 (en) * | 2007-01-22 | 2008-07-31 | The Regents Of The University Of California | Use of antibody conjugates |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103874710A (zh) | 2014-06-18 |
| WO2012135831A1 (en) | 2012-10-04 |
| ES2744840T3 (es) | 2020-02-26 |
| WO2012135831A8 (en) | 2013-11-21 |
| US9701740B2 (en) | 2017-07-11 |
| US20220017609A1 (en) | 2022-01-20 |
| US20140050723A1 (en) | 2014-02-20 |
| JP2014513069A (ja) | 2014-05-29 |
| US10961301B2 (en) | 2021-03-30 |
| US20240247056A1 (en) | 2024-07-25 |
| JP6178785B2 (ja) | 2017-08-09 |
| EP3597665A1 (en) | 2020-01-22 |
| US20170334981A1 (en) | 2017-11-23 |
| JP2016094479A (ja) | 2016-05-26 |
| EP2694555B1 (en) | 2019-07-10 |
| EP2694555A1 (en) | 2014-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240247056A1 (en) | Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair | |
| US20260028426A1 (en) | Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus | |
| US20200199255A1 (en) | Multivalent fragments of antibody 3e10 and methods of use thereof | |
| US20190307883A1 (en) | Cell penetrating nucleolytic antibody based cancer therapy | |
| US12616750B2 (en) | Combination therapy utilizing DNA alkylating agents and ATR inhibitors | |
| US20210340279A1 (en) | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators | |
| US20220288219A1 (en) | Antigen-binding protein constructs and uses thereof | |
| EP4387667A1 (en) | Combination radiotherapy | |
| HK40021615A (en) | Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair | |
| EP4306640A1 (en) | Method for treating a tumor in a subject | |
| CN119654415A (zh) | 治疗受试者中肿瘤的方法 | |
| TW202535479A (zh) | 抗體藥物結合物與血腦屏障穿透性parp1選擇性抑制劑之組合 | |
| IL325297A (en) | Preparations and methods for targeting extracellular DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |